文献速递炎症性肠病

托法替布治疗溃疡性结肠炎的真实世界证据:短期与长期有效性及安全性

Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety.
PubMed 文献 · Am J Gastroenterol · 2022-12-14

这项回顾性多中心研究纳入408例溃疡性结肠炎患者,评估托法替布的短期与长期有效性及安全性。托法替布维持概率6个月为67%、12个月为58%、24个月为49%;第4、8、16周缓解比例分别为38%、45%、47%。安全性特征与既往报道相似。

要点

  • 托法替布维持概率6个月为67%、12个月为58%、24个月为49%。
  • 第4、8、16周缓解比例分别为38%、45%、47%。
  • 171例第8周缓解者中83例(49%)复发,维持应答概率6个月为66%、12个月为54%。

核心结论

  • 托法替布对溃疡性结肠炎患者短期和长期均有效。
  • 安全性特征与既往报道相似。

研究设计与样本

  • 回顾性多中心研究,纳入408例溃疡性结肠炎患者,入组前至少8周接受首剂托法替布。
  • 临床有效性基于部分Mayo评分评估。

主要发现

  • 随访期间184例(45%)停用托法替布,平均随访18个月。
  • 维持托法替布的概率6个月为67%、12个月为58%、24个月为49%。
  • 停用托法替布的主要原因为原发性无应答(44%)。
  • 第4、8、16周缓解比例分别为38%、45%、47%。
  • 171例第8周缓解者中83例(49%)复发;维持应答概率6个月为66%、12个月为54%。

关键数值与推荐

  • 开始托法替布时年龄较大和临床活动度较高与停用托法替布相关。
  • 基线中重度vs轻度疾病活动与第8周缓解可能性较低相关,开始托法替布时年龄较大与第8周缓解可能性较高相关。
  • 共报告93例与托法替布治疗相关的不良事件,包括2例肺血栓栓塞症(患者有危险因素)和2例外周血管血栓形成,其中29例导致停用托法替布。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The objective of this study was to assess the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice. METHODS: This is a retrospective multicenter study including patients with UC who had received the first tofacitinib dose at least 8 weeks before the inclusion. Clinical effectiveness was based on partial Mayo score. RESULTS: A total of 408 patients were included. Of them, 184 (45%) withdrew tofacitinib during follow-up (mean = 18 months). The probability of maintaining tofacitinib was 67% at 6 m, 58% at 12 m, and 49% at 24 m. The main reason for tofacitinib withdrawal was primary nonresponse (44%). Older age at the start of tofacitinib and a higher severity of clinical activity were associated with tofacitinib withdrawal. The proportion of patients in remission was 38% at week 4, 45% at week 8, and 47% at week 16. Having moderate-to-severe vs mild disease activity at baseline and older age at tofacitinib start were associated with a lower and higher likelihood of remission at week 8, respectively. Of 171 patients in remission at week 8, 83 (49%) relapsed. The probability of maintaining response was 66% at 6 m and 54% at 12 m. There were 93 adverse events related to tofacitinib treatment (including 2 pulmonary thromboembolisms [in patients with risk factors] and 2 peripheral vascular thrombosis), and 29 led to tofacitinib discontinuation. DISCUSSION: Tofacitinib is effective in both short-term and long-term in patients with UC. The safety profile is similar to that previously reported.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chaparro M, Acosta D, Rodríguez C, et al. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety. Am J Gastroenterol. 2022. PMID: 36716287. doi:10.14309/ajg.0000000000002145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。